Alphabet’s relentless AI spending is giving new shine to Broadcom’s stock
Alphabet's aggressive AI capex cycle is directly benefiting Broadcom, whose custom silicon and switching chips are gaining analyst attention ahead of earnings. AVGO is up 5.2% today on the news, with Oppenheimer flagging it positively into the print — setting up a momentum-into-earnings trade with elevated expectations to clear.
What happened
Alphabet's aggressive AI capex cycle is directly benefiting Broadcom, whose custom silicon and switching chips are gaining analyst attention ahead of earnings.
The read · Jun 2
Long AVGO into earnings on Alphabet AI capex tailwind — custom ASIC and switching chip demand supports upside, but buy the catalyst not the gap.
Wrong if
Stock has already surged 5.2% on the news — earnings must beat AND guide higher or the trade reverses sharply; GOOGL insider selling (12S/0B last 30d) hints at some insider caution on the hyperscaler itself, which could cap sympathy upside if AI spend narrative cools.
CoverageSource: MarketWatch · Published here TUE, JUN 2 · 11:56 AM ET · the only report in this recordHow this is decided →
The chart · AVGOTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
The read, in fullWhy it matters
Broadcom's custom ASIC business (XPUs for Google, Meta) is a direct beneficiary of hyperscaler AI capex acceleration — Alphabet's $80B equity raise to fund AI expansion is precisely the upstream spending that flows to AVGO. Consensus is heavily skewed SB (17SB/35B/4H) and Oppenheimer sent a positive note today, suggesting the Street is broadly aligned. The risk is that today's 5.2% move has pulled forward much of the near-term upside and any earnings guidance miss will punish aggressively given elevated positioning.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written
Next · what would move this
Into earnings, ~1-2 weeks. Follow to be told when one lands.
Receipts
MarketWatch — the original11:56 AM
Research, not advice.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →
This page is kept as it was written on Jun 2. Later coverage joins it only when the company and catalyst evidence match, and what the stock did is shown from licensed end-of-day closes — never re-graded, never backdated. The judgment is yours.